Role of Insulin Resistance in the Development of Nonalcoholic Fatty Liver Disease in People With Type 2 Diabetes: From Bench to Patient Care

Overview

Journal Diabetes Spectr

Specialty Endocrinology

Date 2024 Feb 22

PMID 38385099

Authors

Juan Patricio Nogueira

Kenneth Cusi

Affiliations

Soon will be listed here.

Abstract

Insulin resistance is implicated in both the pathogenesis of nonalcoholic fatty liver disease (NAFLD) and its progression from steatosis to steatohepatitis, cirrhosis, and even hepatocellular carcinoma, which is known to be more common in people with type 2 diabetes. This article reviews the role of insulin resistance in the metabolic dysfunction observed in obesity, type 2 diabetes, atherogenic dyslipidemia, and hypertension and how it is a driver of the natural history of NAFLD by promoting glucotoxicity and lipotoxicity. The authors also review the genetic and environmental factors that stimulate steatohepatitis and fibrosis progression and their relationship with cardiovascular disease and summarize guidelines supporting the treatment of NAFLD with diabetes medications that reduce insulin resistance, such as pioglitazone or glucagon-like peptide 1 receptor agonists.

Citing Articles

Metabolic dysfunction-associated steatotic liver disease in adults.

Huang D, Wong V, Rinella M, Boursier J, Lazarus J, Yki-Jarvinen H Nat Rev Dis Primers. 2025; 11(1):14.

PMID: 40050362 DOI: 10.1038/s41572-025-00599-1.

Efficacy of Non-invasive Biomarkers in Diagnosing Non-alcoholic Fatty Liver Disease (NAFLD) and Predicting Disease Progression: A Systematic Review.

Garg S, Varghese M, Shaik F, Jatin F, Sachdeva D, Wafa Eranhikkal F Cureus. 2025; 17(2):e78421.

PMID: 40046382 PMC: 11881788. DOI: 10.7759/cureus.78421.

Genomics-Informed Drug Repurposing Strategy Identifies Novel Therapeutic Targets for Metabolic Dysfunction-Associated Steatotic Liver Disease.

Seagle H, Akerele A, DeCorte J, Hellwege J, Breeyear J, Kim J medRxiv. 2025; .

PMID: 40034783 PMC: 11875238. DOI: 10.1101/2025.02.18.25321035.

Natural Bioactive Compounds in the Management of Type 2 Diabetes and Metabolic (Dysfunction)-Associated Steatotic Liver Disease.

Ciobarca D, Catoi A, Gavrilas L, Banc R, Miere D, Filip L Pharmaceuticals (Basel). 2025; 18(2).

PMID: 40006091 PMC: 11859434. DOI: 10.3390/ph18020279.

Assessment of Non-alcoholic Fatty Liver Disease and Level of Risk of Fibrosis in Diabetic and Non-diabetic Individuals.

Wahiduzzaman M, Ferdous N, Haque K, Kabir A, Siddiki M, Hossain M Cureus. 2025; 16(12):e76162.

PMID: 39840152 PMC: 11747980. DOI: 10.7759/cureus.76162.

References

Musso G, Cassader M, Paschetta E, Gambino R . Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis. JAMA Intern Med. 2017; 177(5):633-640. PMC: 5470366. DOI: 10.1001/jamainternmed.2016.9607. View

Angulo P, Kleiner D, Dam-Larsen S, Adams L, Bjornsson E, Charatcharoenwitthaya P . Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2015; 149(2):389-97.e10. PMC: 4516664. DOI: 10.1053/j.gastro.2015.04.043. View

Jonas W, Schurmann A . Genetic and epigenetic factors determining NAFLD risk. Mol Metab. 2020; 50:101111. PMC: 8324682. DOI: 10.1016/j.molmet.2020.101111. View

Koliaki C, Szendroedi J, Kaul K, Jelenik T, Nowotny P, Jankowiak F . Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis. Cell Metab. 2015; 21(5):739-46. DOI: 10.1016/j.cmet.2015.04.004. View

Younossi Z, Golabi P, Paik J, Henry A, Van Dongen C, Henry L . The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023; 77(4):1335-1347. PMC: 10026948. DOI: 10.1097/HEP.0000000000000004. View

Gidener T, Dierkhising R, Mara K, Therneau T, Venkatesh S, Ehman R . Change in serial liver stiffness measurement by magnetic resonance elastography and outcomes in NAFLD. Hepatology. 2022; 77(1):268-274. PMC: 9712594. DOI: 10.1002/hep.32594. View

DeFronzo R, Inzucchi S, Abdul-Ghani M, Nissen S . Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetes. Diab Vasc Dis Res. 2019; 16(2):133-143. DOI: 10.1177/1479164118825376. View

Kanwal F, Shubrook J, Younossi Z, Natarajan Y, Bugianesi E, Rinella M . Preparing for the NASH Epidemic: A Call to Action. Diabetes Care. 2021; 44(9):2162-2172. DOI: 10.2337/dci21-0020. View

Liu D, Peloso G, Yu H, Butterworth A, Wang X, Mahajan A . Exome-wide association study of plasma lipids in >300,000 individuals. Nat Genet. 2017; 49(12):1758-1766. PMC: 5709146. DOI: 10.1038/ng.3977. View

10.

Santos-Baez L, Ginsberg H . Nonalcohol fatty liver disease: balancing supply and utilization of triglycerides. Curr Opin Lipidol. 2021; 32(3):200-206. PMC: 8087156. DOI: 10.1097/MOL.0000000000000756. View

11.

Harrison S, Gawrieh S, Roberts K, Lisanti C, Schwope R, Cebe K . Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort. J Hepatol. 2021; 75(2):284-291. DOI: 10.1016/j.jhep.2021.02.034. View

12.

Fromenty B, Roden M . Mitochondrial alterations in fatty liver diseases. J Hepatol. 2022; 78(2):415-429. DOI: 10.1016/j.jhep.2022.09.020. View

13.

Loomba R, Friedman S, Shulman G . Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell. 2021; 184(10):2537-2564. DOI: 10.1016/j.cell.2021.04.015. View

14.

Varadharajan V, Massey W, Brown J . Membrane-bound O-acyltransferase 7 (MBOAT7)-driven phosphatidylinositol remodeling in advanced liver disease. J Lipid Res. 2022; 63(7):100234. PMC: 9240865. DOI: 10.1016/j.jlr.2022.100234. View

15.

Smith R, Soeters M, Wust R, Houtkooper R . Metabolic Flexibility as an Adaptation to Energy Resources and Requirements in Health and Disease. Endocr Rev. 2018; 39(4):489-517. PMC: 6093334. DOI: 10.1210/er.2017-00211. View

16.

Gastaldelli A, Cusi K . From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options. JHEP Rep. 2020; 1(4):312-328. PMC: 7001557. DOI: 10.1016/j.jhepr.2019.07.002. View

17.

Alexopoulos A, Crowley M, Wang Y, Moylan C, Guy C, Henao R . Glycemic Control Predicts Severity of Hepatocyte Ballooning and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease. Hepatology. 2021; 74(3):1220-1233. PMC: 8518519. DOI: 10.1002/hep.31806. View

18.

Cusi K, Orsak B, Bril F, Lomonaco R, Hecht J, Ortiz-Lopez C . Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial. Ann Intern Med. 2016; 165(5):305-15. DOI: 10.7326/M15-1774. View

19.

Dormandy J, Charbonnel B, Eckland D, Erdmann E, Massi-Benedetti M, Moules I . Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005; 366(9493):1279-89. DOI: 10.1016/S0140-6736(05)67528-9. View

20.

Elkrief L, Rautou P, Sarin S, Valla D, Paradis V, Moreau R . Diabetes mellitus in patients with cirrhosis: clinical implications and management. Liver Int. 2016; 36(7):936-48. DOI: 10.1111/liv.13115. View